August 3, 2009 5:02 PM
- Text
FDA Clears Drug for Kidney Cancer
(AP)
Biotech drugmaker Genentech Inc. said Sunday the Food and Drug Administration approved its cancer treatment Avastin for a new use against a form of kidney cancer, marking the sixth approval for the blockbuster drug.
Avastin is already approved to treat certain types of lung, breast and colon cancer.
FDA regulators cleared the injectable treatment for advanced renal cell carcinoma, the most common form of kidney cancer. Roughly 50,000 new cases of the disease are diagnosed in the U.S. each year, according to the National Cancer Institute.
South San Francisco, Calif.-based Genentech is owned by drugmaker Roche, based in Basel, Switzerland.
Avastin was Genentech's top-selling product last year with revenue of $2.69 billion. However, sales growth has been slowing. Analysts say the drug is likely reaching a saturation point in the market and will need additional FDA approvals to continue growing.
In April, a study showed Avastin failed to prevent colon cancer from recurring in patients who had undergone surgery, sending Roche shares lower in trading.
Initially approved in 2004, Avastin was the first drug to fight cancer by choking off blood flow to tumors. Such "targeted therapies" were considered a significant advance beyond chemotherapy.
Avastin is already approved to treat certain types of lung, breast and colon cancer.
FDA regulators cleared the injectable treatment for advanced renal cell carcinoma, the most common form of kidney cancer. Roughly 50,000 new cases of the disease are diagnosed in the U.S. each year, according to the National Cancer Institute.
South San Francisco, Calif.-based Genentech is owned by drugmaker Roche, based in Basel, Switzerland.
Avastin was Genentech's top-selling product last year with revenue of $2.69 billion. However, sales growth has been slowing. Analysts say the drug is likely reaching a saturation point in the market and will need additional FDA approvals to continue growing.
In April, a study showed Avastin failed to prevent colon cancer from recurring in patients who had undergone surgery, sending Roche shares lower in trading.
Initially approved in 2004, Avastin was the first drug to fight cancer by choking off blood flow to tumors. Such "targeted therapies" were considered a significant advance beyond chemotherapy.
Popular Now in Health
- Cancer drug reverses Alzheimer's in mice: Study
- Marijuana-smoking motorists twice as likely to crash
- 4.5 million Americans over 50 have artificial knees
- Skin cancer self-exam: What to look for (PHOTOS)
- Things You Didn't Know About Your Penis
- Norovirus outbreak hits Rider University in N.J
- John Dye Dies: What Killed "Angel" Star?
- PICTURES: 15 Shocking Sexual Fetishes
- America's sodium problem: Not from salty snacks?
- HealthPop: Online dating and jaw engraving
- Caffeine inhalers - the next club drug?
- Woman spotlights uterus didelphys on talk show
- Chinese mom gives birth to 15-pound baby
- Let's Move! campaign turns 2 today: Is it working?
- Christina Hendricks: Too Big for Hollywood?
- America's pets also have an obesity epidemic
- 8 Tips For Losing Weight After Pregnancy
Latest CBS News Headlines
on Facebook Most Discussed Stories
on CBS News
- Peru: Rebel leader found badly wounded
- W.H. official: Contraceptive rule stands
- Whitney Houston: Music was in her blood
- Iran summons Azeri envoy over Mossad allegations
on Facebook Most Discussed Stories
on CBS News






